In this context, our finding that ACE inhibitor and ARB combination therapy interact to decrease ACE2 gene expression and prevent increases in ACE2 protein levels may offer an avenue to reduce tissue ACE2 in people on ACE inhibitor or ARB monotherapy while still providing protection against cardiovascular or renal disease. This evidence concerns the gene ACE and kidney disorder.